Sign in or create an account to add this stock to your watchlist.
About Arch Therapeutics (OTCMKTS:ARTH)
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ARTH
CUSIPN/A
Phone617-431-2313
Debt
Debt-to-Equity RatioN/A
Current Ratio8.82
Quick Ratio8.82
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book44.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-211.35%
Return on Assets-108.96%
Miscellaneous
Employees10
Outstanding Shares154,050,000
Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions
What is Arch Therapeutics' stock symbol?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How were Arch Therapeutics' earnings last quarter?
Arch Therapeutics (OTCMKTS:ARTH) released its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). View Arch Therapeutics' Earnings History.
What price target have analysts set for ARTH?
3 brokerages have issued 1 year price targets for Arch Therapeutics' stock. Their predictions range from $3.00 to $3.00. On average, they expect Arch Therapeutics' share price to reach $3.00 in the next year. View Analyst Ratings for Arch Therapeutics.
Who are some of Arch Therapeutics' key competitors?
Some companies that are related to Arch Therapeutics include Pulse Biosciences (PLSE), Orthopediatrics (KIDS), Nuvectra (NVTR), IRadimed (IRMD), SeaSpine (SPNE), Apollo Endosurgery (APEN), Restoration Robotics (HAIR), Alphatec (ATEC), Sensus Healthcare (SRTS), INVO Bioscience (IVOB), Motus GI (MOTS), Invuity (IVTY), SANUWAVE (SNWV), Neovasc (NVCN) and iCAD (ICAD).
Who are Arch Therapeutics' key executives?
Arch Therapeutics' management team includes the folowing people:
- Dr. Terrence W. Norchi M.D., Co-Founder, Pres, CEO & Director (Age 53)
- Mr. Richard E. Davis, CFO, Principal Accounting Officer & Treasurer (Age 60)
- Mr. Rutledge Ellis-Behnke Ph.D., Co-Founder and Scientific Advisor
- Dr. Steven A. Kates Ph.D., VP of Technology
- Dr. William Tzocor Denman M.D., MBChB,FRCA, IV, Clinical Advisor (Age 55)
Has Arch Therapeutics been receiving favorable news coverage?
Media headlines about ARTH stock have trended somewhat positive on Thursday, according to Accern Sentiment. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arch Therapeutics earned a media sentiment score of 0.06 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.73 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Arch Therapeutics?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arch Therapeutics' stock price today?
One share of ARTH stock can currently be purchased for approximately $0.44.
How big of a company is Arch Therapeutics?
Arch Therapeutics has a market capitalization of $70.85 million. Arch Therapeutics employs 10 workers across the globe.
How can I contact Arch Therapeutics?
Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]
MarketBeat Community Rating for Arch Therapeutics (ARTH)
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arch Therapeutics (OTCMKTS:ARTH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Arch Therapeutics in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 581.82%. The high price target for ARTH is $3.00 and the low price target for ARTH is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.33 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.00 | $3.00 | $3.00 | $2.8333 |
| Price Target Upside: | 581.82% upside | 915.23% upside | 759.60% upside | 255.18% upside |
Arch Therapeutics (OTCMKTS:ARTH) Consensus Price Target History
Arch Therapeutics (OTCMKTS:ARTH) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Arch Therapeutics (OTCMKTS:ARTH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Arch Therapeutics (OTCMKTS ARTH) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.02%
Arch Therapeutics (OTCMKTS ARTH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Arch Therapeutics (OTCMKTS ARTH) News Headlines
| Source: |
|
Arch Therapeutics (OTCMKTS:ARTH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Arch Therapeutics (OTCMKTS ARTH) Stock Chart for Thursday, May, 24, 2018
Loading chart…
